Catalyst Pharmaceuticals, Inc. (CPRX) Given a $5.00 Price Target by Roth Capital Analysts
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has been assigned a $5.00 target price by equities researchers at Roth Capital in a research note issued to investors on Wednesday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Roth Capital’s price objective would indicate a potential upside of 74.83% from the stock’s current price.
Several other equities analysts have also recently weighed in on CPRX. Zacks Investment Research cut Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Piper Jaffray Companies set a $6.00 price target on Catalyst Pharmaceuticals and gave the company a “buy” rating in a report on Monday, August 7th. Finally, SunTrust Banks, Inc. restated a “buy” rating and set a $5.00 price target on shares of Catalyst Pharmaceuticals in a report on Tuesday, September 5th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Catalyst Pharmaceuticals presently has an average rating of “Buy” and an average price target of $5.50.
Catalyst Pharmaceuticals (CPRX) traded down 2.273% during mid-day trading on Wednesday, reaching $2.795. The company had a trading volume of 743,451 shares. The firm has a 50-day moving average of $2.60 and a 200 day moving average of $2.50. Catalyst Pharmaceuticals has a 1-year low of $0.94 and a 1-year high of $3.20. The company’s market capitalization is $236.33 million.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.01. On average, analysts predict that Catalyst Pharmaceuticals will post ($0.23) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Catalyst Pharmaceuticals, Inc. (CPRX) Given a $5.00 Price Target by Roth Capital Analysts” was originally published by American Banking News and is owned by of American Banking News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/11/01/catalyst-pharmaceuticals-inc-cprx-given-a-5-00-price-target-by-roth-capital-analysts.html.
In related news, insider Patrick J. Mcenany acquired 20,000 shares of the stock in a transaction dated Tuesday, September 5th. The stock was acquired at an average cost of $2.58 per share, with a total value of $51,600.00. Following the purchase, the insider now directly owns 4,471,026 shares of the company’s stock, valued at $11,535,247.08. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 8.79% of the stock is owned by company insiders.
Large investors have recently bought and sold shares of the company. Nationwide Fund Advisors bought a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter valued at approximately $111,000. New York State Common Retirement Fund bought a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter valued at approximately $114,000. Bank of New York Mellon Corp lifted its stake in shares of Catalyst Pharmaceuticals by 3.6% in the 1st quarter. Bank of New York Mellon Corp now owns 69,176 shares of the biopharmaceutical company’s stock valued at $135,000 after purchasing an additional 2,404 shares during the last quarter. State of Wisconsin Investment Board bought a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter valued at approximately $149,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of Catalyst Pharmaceuticals in the 1st quarter valued at approximately $155,000. 40.10% of the stock is owned by institutional investors and hedge funds.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.